ZBH - Educational Analysis * US Equities
Educational Analysis * US Equities

ZBH

Earnings behavior, post-earnings drift, and the gap between consensus and the market's real expectation - the educational primer before you look at the institutional verdict.

Educational content only - not investment advice. Nothing on this page is a recommendation to buy or sell any security. Historical patterns do not predict future outcomes. Consult a licensed financial advisor before making any trading decision.
Published byGamma QC editorial
TickerZBH
CategoryEducational primer
Last reviewedNovember 16, 2026
You're viewing an older edition of this page.Read the latest edition →

Business profile & competitive position

Zimmer Biomet Holdings, Inc. (ZBH) operates in the Healthcare sector, specifically the Medical - Devices industry. The company is a global med-tech firm that designs, manufactures and markets orthopedic reconstructive products, sports medicine and biologics solutions, extremities and trauma devices, craniomaxillofacial and thoracic products, bone cement, surgical products, and integrated digital and robotic technologies that leverage data, analytics and artificial intelligence. Its products treat patients with disorders or injuries affecting bones, joints or supporting soft tissues, and it works with healthcare professionals worldwide to advance surgical innovation.

The financial footprint suggests a stable but not dominant competitive position. The company's 9.0% net margin and 6.1% return on equity (ROE) point to modest profitability rather than a wide economic moat. These figures are respectable for a capital-intensive device maker, but they do not suggest exceptional pricing power or asset efficiency. A notable operating detail from the most recent 10-K is that consignment sales represented approximately 85% of net sales in 2025, meaning inventory largely sits at hospitals or surgical facilities until used. That model can support recurring revenue relationships but also ties working capital closely to procedure volumes. As of December 31, 2025, Zimmer Biomet employed approximately 2,000 research and development employees globally, signaling continued investment in product iteration.

Financial posture

ZBH currently carries a $19.2 billion market capitalization and trades at a price-to-earnings ratio of 25.5. That valuation sits within a range often associated with mature healthcare franchises that are reinvesting for low-to-mid single-digit growth rather than high-growth disruptors. The 9.0% net margin and 6.1% ROE reinforce the picture of a profitable but capital-heavy operator: it generates reliable earnings, yet returns on shareholder equity are restrained by acquisition history, goodwill and the physical inventory tied to consignment sales.

The stock's beta of 0.47 is notably low, implying it has historically moved less than half as much as the broader equity market. That is consistent with a defensive, large-cap healthcare name where demand is driven by elective and emergency procedures rather than cyclical consumer or industrial spending. The current price of $101.36 sits above the 50-day exponential moving average of $97.89, while the RSI of 52.1 indicates neither overbought nor oversold conditions from a technical standpoint. Overall, the financial posture reads as a mid-valuation, low-volatility med-device holding with moderate profitability metrics.

Strategic priorities & outlook

The company's most recent 10-K filing outlines a clear set of near-term operational priorities. First, Zimmer Biomet intends to rapidly commercialize new data solutions, surgical techniques, innovative materials, biologics products, and implant and instrument designs. Second, it aims to broaden offerings in select product categories and explore new technologies, including artificial intelligence and machine learning. Third, growth will partly come from external innovation: the company plans to continue identifying innovative technologies through acquisitions, licensing arrangements or strategic alliances.

Operationally, one of the most significant initiatives is a multi-year effort to convert substantial portions of the U.S. sales force from independent sales agents to employees. That transition can reshape selling economics, training consistency and customer relationships, but it also carries execution risk during the conversion period. Geographically, the company reports through three segments: Americas, EMEA and Asia Pacific. In 2025, the U.S. accounted for approximately 95% of Americas net sales and Japan accounted for approximately 50% of Asia Pacific net sales, which means regional performance will be heavily influenced by those two markets.

Macro & geopolitical exposure

As a Medical - Devices company, ZBH sits at the intersection of healthcare regulation, global supply chains and demographic demand. The industry is heavily regulated by bodies such as the FDA in the United States and equivalent agencies abroad; changes in approval pathways, quality-system enforcement or product recalls can materially affect revenue and margins. Trade policy is another relevant factor, because medical devices and their components are manufactured and sourced across multiple jurisdictions, leaving the group exposed to tariffs, customs delays or preferential trade agreements.

Currency exposure is inherent in the sector, given international sales and regional reporting segments. Reimbursement policy also matters: hospital and insurer reimbursement rates for orthopedic procedures can influence adoption rates for Zimmer Biomet's implants and surgical systems. On the positive side, aging populations in developed markets and expanding access to surgical care in emerging markets create long-term demand tailwinds for orthopedic, trauma and reconstructive devices. Supply-chain resilience—particularly for specialized metals, polymers and sterile packaging—remains an ongoing operational theme across the industry.

Recent developments

The most recent news flow is relatively light on stock-moving catalysts. On November 8, 2026, MarketBeat published "What Zimmer Biomet (ZBH) Said on Its Q3 Earnings Call," summarizing management commentary following the company's third-quarter report. Two days later, on November 9, 2026, PR Newswire reported that the company would present at the Annual Jefferies Global Healthcare Conference in London, a typical venue for med-tech management teams to discuss strategy with investors.

On November 11, 2026, two articles hit the wires: DefenseWorld.net ran a "Financial Contrast" piece comparing Zimmer Biomet with Artivion (AORT), and InvestorPlace included ZBH in a "Best Stocks for 2027" roundup. None of these items constitute definitive fundamental developments, but they do show ongoing sell-side and media attention as the company heads toward its next reporting date.

Earnings behavior & post-earnings drift

ZBH has delivered an impressive earnings consistency record: over the last eight reported quarters, the company has beaten estimates 8 out of 8 times, for a 100% beat rate. The average earnings surprise across that span has been 3.4%. Yet the price action following those beats tells a more nuanced story. The average 5-day post-earnings move across those eight quarters has been +1.26%, classified as an "up" drift directionally.

Drilling into the four most recent quarters reveals the real disconnect. For the quarter reported November 4, 2026, actual EPS of $1.90 beat the $1.88 estimate by 1.1%, yet the stock fell 3% the next day and 2.43% over the following five sessions. The August 5, 2026 quarter delivered a 3.0% beat ($2.07 vs. $2.01), but the stock still slipped 0.99% the next day and 0.28% over five days. The April 28, 2026 quarter showed a large 12.4% beat ($2.09 vs. $1.86), yet the next-day reaction was a 3.3% drop, with only a marginal +0.25% five-day recovery. Only the February 10, 2026 report followed the intuitive script: a 1.7% beat ($2.42 vs. $2.38) drove a 4.61% next-day gain and a 7.49% five-day advance.

The takeaway for traders and analysts is that ZBH's beats have often been priced in—or even overshadowed by guidance, margin commentary or sector rotation. The next scheduled report is February 9, 2027 before the market open, with a consensus EPS estimate of $2.49. The unofficial consensus may differ from the published estimate, but the historical pattern suggests that even a headline beat is no guarantee of a sustained upward price reaction.

Frequently Asked Questions

What does Zimmer Biomet primarily sell?

Zimmer Biomet designs and markets orthopedic reconstructive products, sports medicine and biologics solutions, trauma and extremities devices, craniomaxillofacial and thoracic products, bone cement, surgical products, and digital and robotic technologies used in procedures involving bones, joints and soft tissues.

How has ZBH historically performed immediately after earnings?

Over the last eight quarters the company has beaten EPS estimates 100% of the time with an average surprise of 3.4%, and the average five-day post-earnings drift has been +1.26%. However, the three most recent reports before February 2026 all saw negative next-day price action despite beating estimates.

What are Zimmer Biomet's main strategic priorities?

The 10-K highlights commercializing new data solutions, surgical techniques, materials, biologics and implant designs; expanding AI and machine learning capabilities; pursuing acquisitions, licensing and alliances for new technologies; and converting a large portion of the U.S. sales force from independent agents to employees.

For a deeper dive into how sell-side analysts, institutional holders and quantitative models currently view ZBH ahead of the February 9, 2027 report, review the full institutional verdict on the company.

Real Data - Gamma QC Earnings IntelligenceAs of Nov 16, 2026
Zimmer Biomet Holdings, Inc. · Healthcare / Medical - Devices
$19.2BMarket cap
25.5P/E
9.0%Net margin
6.1%ROE
100%Beat rate, last 8Q
3.4%Avg EPS surprise
1.26%Avg 5-day move after earnings
2027-02-09Next earnings
ReportedActualEstimateSurprise1D Move5D Move
2026-11-04$1.9$1.88+1.1%-3%-2.43%
2026-08-05$2.07$2.01+3%-0.99%-0.28%
2026-04-28$2.09$1.86+12.4%-3.3%+0.25%
2026-02-10$2.42$2.38+1.7%+4.61%+7.49%
2025-11-05$1.9$1.87+1.6%--
2025-08-07$2.07$1.98+4.5%--

Previous ZBH editions

Beyond the primer

Get the institutional verdict on ZBH

Seven-seat 21-ERT council. Pre-print forecast signed before the earnings release. Post-print grade, published in public. Every verdict sealed with a cryptographic receipt.

Read the ZBH verdict at Gamma QC
$49 Pro / $249 RIA * gammaqc.com

Verify authenticity

Every Gamma QC verdict is signed with a cryptographic receipt at issuance. Independently verify any published verdict at attest.gammaqc.com. This educational primer is content-only and not itself signed; the institutional verdict at the link above is.